| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | Yo; CDR62 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CDR2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与CDR2抗体相关的模拟参考文献，内容基于典型研究领域归纳：
---
1. **文献名称**：*CDR2 as an autoantigen in paraneoplastic cerebellar degeneration*
**作者**：Albert, M.L., Darnell, R.B.
**摘要**：该研究揭示了CDR2蛋白在副肿瘤性小脑变性(PCD)中的自身抗原作用，发现患者体内产生的Yo抗体特异性靶向CDR2.并证实其与妇科肿瘤(如卵巢癌)的相关性。研究通过免疫沉淀和Western blot验证了CDR2与抗体的相互作用，为PCD的诊断提供了分子标志物。
---
2. **文献名称**：*Anti-Yo CDR2 antibodies disrupt Purkinje cell calcium signaling in paraneoplastic cerebellar degeneration*
**作者**：Greenlee, J.E., et al.
**摘要**：本文探讨了抗CDR2抗体(Yo抗体)的病理机制，发现其通过干扰小脑浦肯野细胞内的钙离子通道功能，导致神经元退行性变。研究结合体外细胞模型和小鼠实验，揭示了抗体介导的神经毒性通路，为靶向治疗提供了理论依据。
---
3. **文献名称**：*Clinical significance of anti-CDR2 antibodies in neurological syndromes*
**作者**：Shams'ili, S., et al.
**摘要**：该临床研究分析了抗CDR2抗体阳性患者的神经学特征，发现其与快速进展的小脑共济失调、妇科恶性肿瘤高度相关。研究强调早期检测CDR2抗体对肿瘤筛查的价值，并提出了基于抗体滴度的预后评估方法。
---
4. **文献名称**：*Development of a monoclonal antibody targeting CDR2 for cancer immunotherapy*
**作者**：Smith, C., et al.
**摘要**：报道了一种新型抗CDR2单克隆抗体的开发，通过噬菌体展示技术筛选出高亲和力抗体，并在体外实验中证明其可抑制CDR2高表达肿瘤细胞的增殖。研究为CDR2靶向的癌症免疫治疗奠定了基础。
---
**注**：以上文献为示例性质，实际引用时需以真实出版物为准。建议通过PubMed或Google Scholar以关键词“CDR2 antibody”“paraneoplastic cerebellar degeneration”“Yo antibody”检索最新文献。
CDR2 (Cerebellar Degeneration-Related protein 2) antibodies are autoantibodies associated with paraneoplastic neurological syndromes, particularly paraneoplastic cerebellar degeneration (PCD). These antibodies target the CDR2 protein, a cytoplasmic antigen highly expressed in Purkinje cells of the cerebellum and in certain cancers, such as breast or ovarian tumors. CDR2 antibody-positive PCD often manifests as subacute cerebellar ataxia, dysarthria, and oculomotor disturbances, typically preceding cancer diagnosis.
First identified in the 1990s, CDR2 antibodies are part of the broader family of onconeural antibodies, which arise from immune cross-reactivity between tumor antigens and neural tissues (molecular mimicry). Their presence aids in diagnosing paraneoplastic neurological disorders and guides cancer screening. Mechanistically, CDR2 antibodies may disrupt intracellular signaling, though their direct pathogenic role remains debated, as T-cell-mediated cytotoxicity likely contributes to cerebellar damage.
Detection methods include immunohistochemistry, cell-based assays, or immunoblotting. CDR2 antibodies are distinct from CDR2L (CDR2-like) antibodies linked to gynecologic cancers and retinopathy. Clinically, early recognition of CDR2 antibodies is critical for initiating tumor treatment and immunotherapy (e.g., corticosteroids, IVIG), which may stabilize neurological symptoms. Research continues to explore their pathophysiological mechanisms and therapeutic targets.
×
